Ossip Groth: Die Seite wurde neu angelegt: „Entstehender Artikel {| class="wikitable" | | bgcolor="#dfdfdf" | '''Siehe auch''' | align="left" width="800" | |- | bgcolor="#d…“

2010-04-15T15:00:44Z

Die Seite wurde neu angelegt: „miniatur|Entstehender Artikel {| class="wikitable" | | bgcolor="#dfdfdf" | '''Siehe auch''' | align="left" width="800" | |- | bgcolor="#d…“

Neue Seite

[[Datei:pptpdtjpg1.png|miniatur|Entstehender Artikel]]
{| class="wikitable" |
| bgcolor="#dfdfdf" | '''Siehe auch'''
| align="left" width="800" |
|-
| bgcolor="#dfdfdf" | '''Freie Übersichtsartikel'''
| align="left" width="800" |
<ref name="PMID15163298">Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocr Relat Cancer 11(2):191-205 (2004) PMID 15163298 </ref><ref name="PMID15229351">Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229(7):567-85 (2004) PMID 15229351 </ref><ref name="PMID17442674">The non-mevalonate pathway of isoprenoid precursor biosynthesis. J Biol Chem 282(30):21573-7 (2007) PMID 17442674 </ref><ref name="PMID2026581">Protein N-myristoylation. J Biol Chem 266(14):8647-50 (1991) PMID 2026581 </ref><ref name="PMID17476354">Geranylgeranyltransferase I as a target for anti-cancer drugs. J Clin Invest 117(5):1223-5 (2007) PMID 17476354 </ref><ref name="PMID16543601">Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras. J Lipid Res 47(5):883-91 (2006) PMID 16543601 </ref><ref name="PMID16477080">Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 47(4):681-99 (2006) PMID 16477080 </ref><ref name="PMID16401880">Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res 47(3):467-75 (2006) PMID 16401880 </ref><ref name="PMID16339110">Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res 47(2):233-40 (2006) PMID 16339110 </ref><ref name="PMID16278491">Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47(1):15-31 (2006) PMID 16278491 </ref><ref name="PMID16251722">Absorption and lipoprotein transport of sphingomyelin. J Lipid Res 47(1):154-71 (2006) PMID 16251722 </ref><ref name="PMID16207929">Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res 46(12):2531-58 (2005) PMID 16207929 </ref><ref name="PMID1479283">Biochemistry of protein prenylation. J Lipid Res 33(12):1731-40 (1992) PMID 1479283 </ref><ref name="PMID15837619">Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7(4):297-300 (2005) PMID 15837619 </ref><ref name="PMID10412976">New insights into the interaction of Ras with the plasma membrane. Cell 98(1):9-12 (1999) PMID 10412976 </ref><ref name="PMID8807811">Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics. Chem Biol 2(12):787-91 (1995) PMID 8807811 </ref><ref name="PMID11412856">Prenylation of Rab GTPases: molecular mechanisms and involvement in genetic disease. FEBS Lett 498(2-3):197-200 (2001) PMID 11412856 </ref><ref name="PMID9519404">Isoprenoid biosynthesis: manifold chemistry catalyzed by similar enzymes. Structure 6(2):127-33 (1998) PMID 9519404 </ref><ref name="PMID9309215">Electrostatic interaction of myristoylated proteins with membranes: simple physics, complicated biology. Structure 5(8):985-9 (1997) PMID 9309215 </ref>
|-
| bgcolor="#dfdfdf" | '''Wichtige Übersichtsartikel'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Medline Suchterm/ Synonyme'''
| align="left" width="800"|
|-
| bgcolor="#00dfdf" | '''Was ist das'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Struktur'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Physiologie'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Knockout'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Transgen'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Mutation'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Polymorphismus'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Genexpression'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Inhibitoren'''
| align="left" width="800"|
|-
| bgcolor="#dfdfdf" | '''Agonisten'''
| align="left" width="800"|
|}

----

== Bibliographie ==
<references />

{{LinkWP_Miniartikel|Txt=Prenylierung|Link=}}

Prenylierung - Versionsgeschichte

Ossip Groth: Die Seite wurde neu angelegt: „Entstehender Artikel {| class="wikitable" | | bgcolor="#dfdfdf" | '''Siehe auch''' | align="left" width="800" | |- | bgcolor="#d…“